local_hospital

Centre Hospitalier De Saint-Denis

Address
lock Available on a paid plan

Oncology and Digestive Cancer Research

At Centre Hospitalier De Saint-Denis, clinical research in oncology is strongly focused on colorectal cancer, colon carcinoma, small bowel adenocarcinoma, and ampullary adenocarcinoma. These studies are designed to improve treatment effectiveness, refine surgery-related strategies, and evaluate new combinations of cancer therapy for people with locally advanced or metastatic disease.

  • Testing better treatment approaches for colorectal cancer and colon carcinoma
  • Evaluating therapy options for small bowel adenocarcinoma and ampullary adenocarcinoma
  • Improving the success of digestive system cancer care through new treatment strategies

These trials reflect a broad effort to advance care for digestive tract neoplasms while supporting more personalized and effective cancer treatment.

Emergency Care, Stroke, and Cardiovascular Diseases

The site also conducts important studies in stroke, ischemic stroke, large vessel occlusion, myocardial infarction, and other cardiovascular diseases. Research here aims to improve urgent treatment decisions, restore blood flow more effectively, and strengthen outcomes for patients with time-sensitive vascular emergencies.

  • Comparing treatment strategies for large ischemic stroke and large vessel occlusion
  • Assessing ways to improve recovery after cerebral infarction and transient ischemic attack
  • Studying therapies that may reduce complications in cardiovascular disease

These investigations support faster and more effective care for patients facing serious neurological and cardiac emergencies.

Infectious Diseases and Critical Care

Research in infectious diseases at this hospital includes ventilator-associated pneumonia, sepsis, severe bacterial infections, HIV, and herpes simplex virus encephalitis. Many of these studies focus on improving infection control, comparing antibiotic strategies, and identifying safer ways to manage serious illness in intensive care.

  • Evaluating better treatment choices for ventilator-associated pneumonia and sepsis
  • Studying approaches to reduce antibiotic use while maintaining effectiveness
  • Exploring improved care for HIV and severe viral or bacterial infections

The research aims to help clinicians choose treatments that are both effective and appropriate for critically ill patients.

Maternal, Neonatal, and Pediatric Care

Another major area of work covers pregnancy complications, postpartum hemorrhage, preterm rupture of membranes, neonatal respiratory distress, and newborn resuscitation. These studies are focused on improving outcomes for mothers, babies, and children through better emergency care, symptom relief, and prevention of complications.

  • Testing strategies to reduce bleeding and complications after delivery
  • Improving care for preterm birth and newborn respiratory problems
  • Assessing methods to support delivery room resuscitation and pediatric pain control

Work in this area highlights the hospital’s interest in safer obstetric and neonatal care, especially in urgent clinical situations.

Neurology, Metabolic Disorders, and Supportive Care

Clinical trials also address neurological and metabolic conditions such as hereditary retroperitoneal fibrosis, severe hyponatremia, sarcoidosis, and pain related to sickle cell disease. The purpose of this research is to improve symptom control, protect patients from treatment-related complications, and clarify the value of supportive therapies.

  • Studying ways to prevent dangerous changes in blood sodium levels
  • Evaluating pain relief and comfort measures in sickle cell disease
  • Assessing treatments that may improve longer-term recovery in neurological and inflammatory conditions

These studies show a strong interest in supportive care that can make treatment safer and more tolerable for patients with complex illnesses.

Digestive System Disease and Hepatic Research

The research portfolio includes studies of cirrhosis, portal hypertension, and related complications, with the goal of improving how liver disease is managed over time. Investigators are also examining treatment approaches that may better control pressure changes in the liver and reduce the risk of serious outcomes.

  • Improving management of portal hypertension in cirrhosis
  • Testing therapies that may reduce complications of advanced digestive system disease
  • Exploring ways to strengthen long-term liver-related care

This work adds an important gastroenterology dimension to the site’s broader clinical research activity.

Site Overview

assignment
28
connected trials
corporate_fare
11
sponsors
science
79
IMPs

Activity Indicator

Last 6 months

3
Trials started
+50% vs previous period.
2
Trials started 6–12 months ago
28
Total trials linked
Highly Active
trending_upGrowing+50%
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 16 therapeutic areas and 15 of 79 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 62 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
26
Sponsors (total)
11
Active sponsors
10

Sponsor Network

Top 10 by active trials.

lock +9 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +2 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
28
Outperforms 84% of sites
public
Therapeutic diversity
16areas
Outperforms 91% of sites
groups
Sponsor diversity
11sponsors
Outperforms 78% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier De Saint-Denis

lock Showing 1 of 28 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Comparative Study of Doravirine/Lamivudine Versus Dolutegravir/Lamivudine for Maintenance Therapy in HIV Patients with Suppressed Viral LoadANRS Maladies Infectieuses Emergentes, Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le SidaPhase IIIRecruitingApr 2025

IMP list

lock Showing 1 of 79 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil6Unknown2024-02-092026-05-07

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.